ANSTO new state-of-the-art nuclear medicine facility gets license

Huge Two-Day Clean Sweep Auction July 24-25th. Click Here to Bid!

advertisement
Current Location:
>
>
> This Story

Forward Printable StoryPrint Comment
advertisement

 

advertisement

 

Molecular Imaging Homepage

BTG to invest in Chinese medical isotope diagnosis and treatment company Chengdu New Radiomedicine Technology

NorthStar Medical Radioisotopes announces construction completion of Beloit, Wisconsin processing facility

MEDraysintell releases its new Early Stage Radiopharmaceuticals Report

The Innovation Center for Translational Imaging of Tel Aviv University acquires MILabs VECTor PET/SPECT/CT system

New system overcomes challenges of nanotheranostics

Bruker acquires preclinical and molecular imaging research software provider PMOD Technologies

ASRT opposes NRC proposed changes to radiopharmaceutical training and experience standards

Nuclear stress test helps identify heart attack risk in people with diabetes

New combination therapy established as safe and effective for prostate cancer

Standard defines measurement methods for performance parameters of SPECT scanners

ANSTO new state-of-the-art nuclear medicine facility gets license

Press releases may be edited for formatting or style
ANSTO’s new state-of-the-art Nuclear Medicine (ANM) facility has received a licence from the independent regulator and has begun supplying nuclear medicine to Australian patients.

Since April, ANSTO has undertaken limited manufacturing of molybdenum-99 (Mo-99) from the new ANM facility, which will now move into full production of the lifesaving medicine.

Story Continues Below Advertisement

Servicing GE Nuclear Medicine equipment with OEM trained engineers

We offer full service contracts, PM contracts, rapid response, time and material,camera relocation. Nuclear medicine equipment service provider since 1975. Click or call now for more information 800 96 NUMED



Mo-99 is the parent isotope of technetium-99m (Tc-99m), which is used in approximately 85 per cent of all Australian nuclear medicine procedures.

Australians who have received SPECT and SPECT CT scans for the accurate diagnosis of various heart, lung and musculoskeletal conditions, as well as cancers, have benefited from this ANSTO medicine.

It is the world’s most commonly used nuclear medicine, with tens of millions of patients needing access to the medicine around the world every year.

Depending on demand and supply, which fluctuates from week to week, ANM has the ability to meet up to 25 per cent of global needs.

“This is the most advanced and safest manufacturing facility for nuclear medicine on the planet today,” said ANSTO CEO Dr Adi Paterson.

“This is a highly sophisticated manufacturing facility that will see the Shire contributing strongly to health outcomes for patients across Australia, and the wait has been worth it!”

“This facility will ensure supply of vital nuclear medicine for Australians well into the future, and also provide an opportunity for Australia to be a global leader in this industry and export to a global market.

“Nothing like this highly-specialised facility has ever been delivered in Australia before, and I thank everyone who has worked to make this a reality over a significant construction and licencing period.

“The staff at ANM have done a great job of ensuring the successful first limited production from ANM, and in achieving a licence, and we would like to take this opportunity to thank all of them,” Dr Paterson said.

Sutherland Shire Mayor, Councillor Carmelo Pesce, welcomed the new facility.

“ANSTO is one of the biggest employers in the region, so there are local benefits, but this new nuclear medicine facility will take the health benefits global,” said Mayor Pesce.

Through this new medicine facility, and projects like the ANSTO Innovation Precinct which Council are working on with ANSTO, we are helping to introduce hundreds of new jobs to the Shire, and strengthening our region’s grip on the smart jobs of the future.”

From early next decade, the waste produced by the facility will be treated on site at Lucas Heights using ANSTO’s Synroc facility, which is also part of this project, and is currently under construction.

The waste will then be transported to a National Radioactive Waste Management Facility once it has been sited and constructed.

Molecular Imaging Homepage


You Must Be Logged In To Post A Comment